Xencor (NASDAQ:XNCR) Hits New 1-Year Low at $16.00

Xencor, Inc. (NASDAQ:XNCR)’s stock price reached a new 52-week low on Wednesday . The company traded as low as $16.00 and last traded at $16.08, with a volume of 565162 shares changing hands. The stock had previously closed at $17.85.

Wall Street Analyst Weigh In

XNCR has been the topic of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $32.00 price target on shares of Xencor in a research note on Tuesday. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price target on shares of Xencor in a report on Tuesday. Raymond James decreased their target price on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating on the stock in a research report on Friday, June 14th. BTIG Research dropped their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Finally, Wedbush reissued an “outperform” rating and set a $34.00 target price (down previously from $36.00) on shares of Xencor in a research report on Thursday, June 13th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.44.

Xencor Stock Performance

The firm has a market capitalization of $972.99 million, a price-to-earnings ratio of -7.55 and a beta of 0.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. The stock’s fifty day moving average is $20.25 and its two-hundred day moving average is $21.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.25). The company had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. Xencor’s revenue was down 62.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.37) earnings per share. Analysts forecast that Xencor, Inc. will post -3.56 earnings per share for the current year.

Insider Activity at Xencor

In other news, VP John R. Desjarlais sold 36,329 shares of Xencor stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the transaction, the vice president now directly owns 192,319 shares of the company’s stock, valued at approximately $3,523,284.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Diversified Trust Co boosted its stake in Xencor by 4.5% during the first quarter. Diversified Trust Co now owns 13,059 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 563 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Xencor by 2.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,798 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 615 shares during the last quarter. Texas Permanent School Fund Corp boosted its holdings in Xencor by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 690 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its holdings in Xencor by 1.6% during the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock worth $826,000 after buying an additional 699 shares in the last quarter. Finally, Baillie Gifford & Co. grew its position in Xencor by 3.3% in the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 744 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.